Neal Bhai Reports (NBR) — Cipla Rises On U.S. FDA Nod For Immunodeficiency Drug – Shares of the Mumbai-based drugmaker rose as much as 6.47 percent to Rs 622.75 after U.S. FDA gave its final approval to Efavirenz tablets in strength of 600 mg. Efavirenz Tablets 600 mg is AB-rated generic therapeutic equivalent version of Bristol-Myers Squibb Pharma Company’s Sustiva which is used in treatment of human immunodeficiency virus type 1 infection, Cipla said in an exchange filing.
Stock Price
Bond Yield Drops On Reserve Bank’s OMO Plan
Bond Yield Drops On Reserve Bank’s OMO Plan – Yield on India’s 10-year 7.17 percent bond expiring in January 2028 dropped 4 basis points to 7.82 percent …
Stocks Check : Cipla, State Bank Of India And More
Stocks Check: Cipla, State Bank Of India And More 📌 State Bank of India won’t be able to merge more banks with self. 📌 UPL-led …
Indian Stock Market Is Driven By Traders From One City
Gold Silver Reports (GSR) – Indian Stock Market Is Driven By Traders From One City – A record number of Indians now have demat accounts but India remains a traders’ stock market driven by one city: Mumbai.
Pokarna Declines After Well Known Investor Sells Stake
Gold Silver Reports (GSR) – Pokarna Declines After Well Known Investor Sells Stake – Shares of the Secunderabad-based company engaged in business of granite quarrying fell as much as 3 percent to Rs 174.50 after well-known investor Ashish Kacholia sold 1.2 percent stake in the company.
Vedanta Set For Its Longest Losing Streak In Over Three Months
Gold Silver Reports (GSR) – Vedanta Set For Its Longest Losing Streak In Over Three Months – Shares of the metal maker extended its decline for the seventh straight session today, its longest losing streak since March 9. The stock fell as much as 3.3 percent to hit a 52-week low at Rs 230.65 apiece.
BSE Drops Two Pharma Stocks From Sensex; Replaces Them With Private Banks
Gold Silver Reports (GSR) – BSE Drops Two Pharma Stocks From Sensex; Replaces Them With Private Banks – The S&P BSE Sensex will include two more banks from mid-Dec. while two pharmaceutical stocks will exit the index.